微粒化非诺贝特对Ⅱ型糖尿病高脂血症的疗效  

Effect of Fenofibrate on Hyperlipidemia in NoninsulinDependent Diabetes Mellitus

作　　者：方文军[1] 左静南[1] 邢惠莉[1] 王为幸[1] 秦利[1] 

机构地区：[1]上海第二医科大学附属新华医院内分泌科,200092

出　　处：《上海第二医科大学学报》1999年第2期142-143,149,共3页Acta Universitatis Medicinalis Secondae Shanghai

摘　　要：目的观察微粒化非诺贝特对Ⅱ型糖尿病患者高脂血症的疗效及其安全性。方法对35例Ⅱ型糖尿病伴高脂血症患者予以口服微粒化非诺贝特（0．2g／d），共8周。结果微粒化非诺贝特能明显降低血清TG，TC，LDL－Ch，ApoB100（P均＜0．01），升高HDL－Ch（P＜0．01），且降低血尿酸与纤维蛋白原含量（P均＜0．01）。不良反应少而轻微。结论微粒化非诺贝特是调节Ⅱ型糖尿病患者血脂紊乱安全有效的药物。Objective To evaluat the therapeutic effect and safety of fenofibrate on hyperlipidemia in NIDDM patients. Methods Thirty-five NIDDM patients with hyperlipidemia were treated with fenofibrate (0.2g/d) for 8wks. Res'lts After treatment for 8weeks TG, TC, LDL-Ch and ApoB100 declined and HDL-Ch increased significantly (P＜0.01). Fenofibrate also decreased serum urinary acid and fibrinogen. Adverse reactions were mild. Conclusion it suggests that fenofibrate is effective and safe in NIDDM patients with hyperlipidemia.

关 键 词：非诺贝特 高脂血症 糖尿病 药物疗法 

分 类 号：R589.205[医药卫生—内分泌] R972.6[医药卫生—内科学]